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 Central to the pathogenesis of IgA neph-
ropathy (IgAN) is the formation of circu-
lating IgA immune complexes (IgA-ICs) 
that have propensity for mesangial depo-
sition and triggering of glomerular injury. 
Th e underlying mechanisms culminating 
in IgA-IC formation are unclear and 
probably multifaceted. Although IgA-IC 
formation is thought to be universal in 
IgAN, clinical features, biopsy fi ndings, 
and disease progression are highly varia-
ble, with less than half of patients develop-
ing progressive renal disease leading to 
end-stage renal failure. Patients in whom 
IgAN runs a benign course, the non-
 progressors, cannot currently be identi-
fi ed from progressors at diagnosis. An 
ability to stratify patients at risk of pro-
gression at diagnosis would greatly assist 
with the tailoring of treatment, manage-
ment of follow-up, and planning of renal 
replacement therapy. Vuong  et al. 1 (this 
issue) report on a potential new biomar-
ker of risk of progression in IgAN. Th ey 
identifi ed diff erences in the serum levels 
of soluble CD89 – IgA complexes in IgAN, 
with progressors having significantly 
lower levels than non-progressors. Not 
only might this study have implications 
for the future risk stratifi cation of patients 
with IgAN, but these observations also 
raise interesting questions regarding the 
role of CD89 in formation of pathogenic 
IgA-ICs in IgAN. 
 CD89 (Fc  RI) belongs to a class of 
receptors that bind the Fc portion of 
immunoglobulins. 2 It is specifi c for IgA 
and binds both monomeric IgA1 and IgA2 
with low affinity, while polymeric IgA 
(pIgA) binds with high avidity. CD89 can 
exist in multiple forms and is present on 
monocytes and macrophages, neutrophils, 
eosinophils, dendritic cells, and Kupff er 
cells, but not mesangial cells. It is a trans-
membrane glycoprotein that apparently 
lacks intrinsic signal-transduction capa-
bility; however, it can associate with FcR  
chains that have tyrosine-based activation 
motifs in their cytoplasmic domains. 
Th ese FcR  chains are also shared with 
other types of FcRs and immunoreceptors, 
such as the T-cell receptor complex. IgA 
binding to the CD89 – FcR  complex initi-
ates a downstream cascade of events that 
trigger a variety of inflammatory res-
ponses, including phagocytosis, release of 
infl ammatory cytokines, oxidative burst, 
and antibody-dependent cell-mediated 
cytotoxicity. 
 CD89 can also exist in a soluble form 
(sCD89) following IgA-dependent 
shedding from the surface of a range of 
myeloid cells. 3 – 5 At least three isoforms 
of sCD89 exist. Each comprises the extra-
cellular domain of CD89; they diff er pre-
dominantly in the extent of post- translational 
glycosylation. Of these, a 50- to 70-kDa 
and a 30-kDa isoform appear to play a 
role in IgA-IC formation in IgAN. An 
eosinophil / neutrophil-derived third sol-
uble isoform is generated by alternative 
splicing of the primary gene transcript of 
CD89. Th is isoform has, however, been 
identifi ed only  in vitro , with no current 
evidence for  in vivo function. 4 
 Th e 50- to 70-kDa sCD89 isoform has 
been found exclusively in the serum of 
patients with IgAN and is thought to be 
generated following binding of pIgA with 
CD89 unassociated with FcR  . 5 It has 
been proposed that in IgAN there is spe-
cifi c pIgA-induced shedding into the cir-
culation of this isoform from myeloid 
cells, and that released sCD89 – pIgA com-
plexes amplify the molecular size of circu-
lating IgA-ICs and promote mesangial 
IgA deposition ( Figure 1a ). Mice trans-
genic for human CD89 develop circulat-
ing sCD89 – pIgA complexes, mesangial 
IgA deposition, and hematuria and pro-
teinuria. 5 Infusion of serum sCD89 – pIgA 
complexes from these transgenic mice 
triggers the same renal disease in wild-
type mice. A lack of requirement for FcR  
in shedding of this sCD89 isoform has 
been confirmed in transgenic mice 
expressing a mutated form of CD89 that 
is unable to associate with FcR  . Th ese 
mice also develop circulating sCD89 –
 pIgA complexes, IgA deposits, and hema-
turia. Although CD89 shedding occurs 
following binding of murine pIgA in these 
transgenic models, there is evidence that 
not all human IgA is capable of triggering 
release of sCD89. Using SCID-CD89 
transgenic mice, Launay  et al. were able to 
show that IgA from patients with IgAN 
triggered mesangial IgA deposition but 
had no eff ect in wild-type mice, while IgA 
from healthy controls had no eff ect, sug-
gesting that specifi c changes in circulating 
IgA are responsible for the shedding of the 
50- to 70-kDa sCD89 isoform in IgAN. 5 
Certainly there is  in vitro evidence that 
monomeric IgA (mIgA) isolated from 
patients with IgAN binds with a much 
lower affi  nity to CD89 than mIgA from 
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healthy subjects. 6 It has been proposed 
that this reduced affi  nity of mIgA may 
result in less competition with pIgA for 
occupancy of cell-surface CD89 and con-
sequently a greater likelihood of pIgA 
binding and CD89 shedding. Consistent 
with this hypothesis is the observation 
that numbers of CD89 molecules on 
peripheral monocytes and neutrophils are 
significantly reduced in IgAN. 7 Any 
model proposing a key role for the 50- to 
70-kDa sCD89 isoform in IgA-IC forma-
tion and mesangial IgA deposition in 
IgAN must, however, be supported by evi-
dence of glomerular sCD89 deposition, 
and to date there is no evidence for 
mesangial sCD89 deposition in human 
disease. Whether a failure to identify 
sCD89 in the glomerulus is due to poor 
antigen retrieval and inaccessibility to 
antibody recognition sites within sCD89 –
 pIgA complexes is unclear. Until there is 
clear evidence for mesangial deposition of 
sCD89 in IgAN, the role of the 50- to 70-
kDa sCD89 isoform in the pathogenesis 
of IgAN will remain uncertain. 
 Distinct from the 50- to 70-kDa iso-
form, a smaller and less glycosylated 30-
kDa monocyte-derived sCD89 isoform 
has also been identifi ed. Th is isoform is 
found in serum covalently linked with 
pIgA 8  and is the isoform measured in the 
study by Vuong  et al. 1 In contrast with the 
50- to 70-kDa isoform, shedding of this 
30-kDa isoform is FcR  -dependent, and 
it is present in the serum of both healthy 
subjects and patients with IgAN. 9 Consist-
ent with earlier reports,  Vuong 
 et al. 1 found no difference in levels of 
sCD89 – pIgA complexes between IgAN 
patients, healthy controls, and matched 
subjects with biopsy-proven glomerulone-
phritis from non-IgAN causes. However, 
within the IgAN group, they detected for 
the first time a significant association 
between levels of sCD89 – pIgA complexes 
and likelihood of developing progressive 
renal disease. A previous study by the 
same group, albeit using a diff erent assay, 
had in fact failed to demonstrate any asso-
ciation between the amount of sCD89 –
 pIgA complexes and the level of 
proteinuria or renal function at the time 
of venous sampling. 9 In their present 
study, lower levels of sCD89 – pIgA com-
plexes were associated with an increased 
risk of progression, while higher levels of 
sCD89 – pIgA complexes appeared to be 
protective. In an attempt to explain these 
fi ndings, Vuong  et al. 1 looked at fi ve sin-
gle-nucleotide polymorphisms (SNPs) in 
the gene for CD89 but failed to fi nd any 
association with either IgAN or risk of 
progression. Th ey did, however, identify a 
single SNP associated with lower produc-
tion of sCD89 – pIgA complexes, suggest-
ing a possible influence of CD89 gene 
polymorphisms on production of the 
30-kDa sCD89 isoform. 
 Th e fi ndings of Vuong  et al. 1 appear to 
run contrary to the data concerning the 50- 
to 70-kDa sCD89 isoform, which point to 
an important pathogenic role of sCD89 –
 pIgA complexes in IgAN. Vuong  et al. 1 do, 
however, speculate that the low levels of 
sCD89 – pIgA complexes seen in their 
patients with progressive disease could in 
fact be due to their preferential deposition 
within the glomerulus and therefore instan-
taneous  ‘ consumption ’ from the  circulation. 
Th ere is emerging evidence from our group 
that changes in  O -glycosylation of the IgA1 
hinge region are more marked in patients 
with progressive disease, and it is not 
unreasonable to suggest that undergalacto-
sylated IgA1 molecules may preferentially 
interact with CD89 and promote shedding 
and formation of sCD89 – pIgA complexes 
that have a greater propensity for mesang-
ial deposition. The principal argument 
against this hypothesis is again the persist-
ent inability to fi nd sCD89 in renal biopsies 
of patients with IgAN. 
 An alternative, and perhaps more 
intriguing, possibility is that shedding of 
pIgA complexed with the 30-kDa sCD89 
isoform is protective in IgAN. Th ere is 
increasing evidence that IgAN is associ-
ated with the development of IgG (and 
IgA) anti-IgA1 autoantibodies. 10 Th ese 
autoantibodies appear to be specifi c for 
undergalactosylated IgA1 molecules, 
which are found at increased levels in the 
serum in IgAN, and lead to the formation 
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 Figure 1  |  Binding of pIgA to CD89 can induce shedding of a soluble CD89-pIgA complex from 
the surface of a variety of myeloid cells . The nature of the shed CD89 molecule appears to be 
dependent on the FcR  chain and biochemical properties of the pIgA. In IgA nephropathy release of 
a 50 – 70  kDa soluble CD89 isoform is thought to promote IgA immune complex formation ( a ) while 
shedding of a smaller 30  kDa isoform-pIgA complex may protect pIgA from recognition by circulating 
anti-IgA autoantibodies and thereby reduce the rate of IgA immune complex formation ( b ). 
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of circulating IgA-ICs. Immune com-
plexes containing undergalactosylated 
IgA1  O- glycoforms have been shown 
 in vitro to bind with high affinity to 
mesangial cells, triggering proliferation 
and increased synthesis of extracellular 
matrix components. It is tempting to 
speculate that these anti-IgA1 autoanti-
bodies could be prevented from binding 
to undergalactosylated IgA1 if it is already 
complexed with the 30-kDa sCD89 iso-
form ( Figure 1b ). Th e diff erences between 
progressors and non-progressors seen in 
the study by Vuong  et al. 1 could refl ect 
pIgA-specifi c eff ects on myeloid CD89 
shedding or an inherent predisposition 
of myeloid cells to shed CD89 in response 
to pIgA binding, or a combination of the 
two. With regard to the latter, Vuong 
 et al. 1 already have evidence that CD89 
gene polymorphisms infl uence produc-
tion of the 30-kDa sCD89 isoform. Reg-
ulation of CD89 shedding by pIgA is 
poorly understood, and there are cur-
rently no data concerning the features of 
pIgA that promote CD89 shedding or 
control of diff erential shedding of the 30-
kDa and 50- to 70-kDa sCD89 isoforms. 
 Clearly, further work is required to 
determine the relationship between 
sCD89 – pIgA complexes and pathogenic 
IgA1 – IgG and IgA1 – IgA immune com-
plex formation in IgAN. Crucially, a 
defi nitive study is required to determine 
whether sCD89 is co-deposited with IgA. 
If the findings of Vuong  et al. 1 can be 
reproduced, and formation of sCD89 –
 pIgA complexes is confi rmed to be pro-
tective, this will open up potential new 
avenues both for risk-stratifying patients 
at diagnosis and, if we can manipulate the 
extent of CD89 shedding, for reducing the 
availability of pIgA for anti-IgA1 autoan-
tibodies and consequently the production 
of pathogenic IgA-ICs in IgAN. 
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